12:00 AM
 | 
Aug 24, 2009
 |  BC Week In Review  |  Company News  |  Deals

Noven, Hisamitsu Pharmaceutical Co. Inc. deal

Hisamitsu completed its initial tender offer for Noven, acquiring about 21.9 million shares (87.4%) at $16.50, or about $362 million. The figure...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >